Cyclobenzaprine HCl (also known as MK130; Flexeril), the hydrochloride salt of Cyclobenzaprine, is a potent muscle relaxant by blocking pain sensations, used as a medication for the treatment of skeletal muscle spasms and associated pain in acute musculoskeletal conditions.
PRX-08066 maleic acid (MT500; MT-500; PRX 08066; PRX08066), the maleic acid salt of PRX08066, is a novel, potent and selective 5-HT2B receptor antagonist with important biological activity.
Atomoxetine HCl (formerly LY139603; LY-139603; Tomoxetine; Strattera; Tomoxetina; Tomoxetinum), the hydrochloride salt of Atomoxetine, is a potent and selective norepinephrine (NE) transporter/reuptate inhibitor that has been used for treating attention-deficit hyperactivity disorder (ADHD).
Zolmitriptan (311C90; 311 C90; trade names AscoTop, Zomig, Zomigon, Zomigoro), an approved drug for the treatment of acute migraines, is a potent and highly selective 5-HT(1B/1D) receptor agonist of the triptan class.
Flopropione is a spasmolytic or antispasmodic agent, acting as a 5-HT1A receptor antagonist and also a catechol-o-methyltransferase (COMT) inhibitor.
Ramosetron hydrochloride is a novel and potent serotonin 5-HT3 receptor antagonist.
Aripiprazole (formerly OPC-14597; OPC 14597; OPC14597; trade name Abilify) is an approved atypical antipsychotic drug that acts as a high-affinity partial agonist of 5-HT receptor.
Eltoprazine HCl (formerly DU-28853; DU28853 hydrochloride) is a novel and potent serenic or antiaggressive agent which also acts as an agonist at the 5-HT1A and 5-HT1B receptors and as an antagonist at the 5-HT2C receptor.
Blonanserin (formerly AD 5423; AD-5423; AD5423) is an atypical antipsychotic agent acting as a relatively selective serotonin (5-HT)2A and dopamine D2 antagonist with the potential to be used for the treatment of schizophrenia.
Pimavanserin (formerly ACP-103; BVF-036; trade name Nuplazid) is an orally bioactive and selective inverse agonist of the 5-HT2A (serotonin receptor subtype 2A, pIC50 and pKd of 8.73 and 9.3, respectively) receptor approved as an atypical antipsychotic for the treatment of Parkinson’s disease psychosis.